Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of lapatinib resistance in HER2-driven breast cancer.

Cancer treatment reviews - 1 Dec 2015

D'Amato Valentina, Raimondo Lucia, Formisano Luigi, Giuliano Mario, De Placido Sabino, Rosa Roberta, Bianco Roberto

Abstract excerpt

Targeted therapies have been approved for various malignancies but the acquisition of resistance remains a substantial challenge in the clinical management of advanced cancers. Twenty-five per cent of breast cancers overexpress ErbB2/HER2, which confers a more aggressive phenotype and is associated with a poor prognosis. HER2-targeting therapies (trastuzumab, pertuzumab, TDM1 and lapatinib) are available, but a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lapatinib

Share to Phosphotransferases

Share to Protein-Tyrosine Kinases

Share to Quinazolines

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Source

Identifiers

PMID: 26276735
DOI: 10.1016/j.ctrv.2015.08.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of lapatinib resistance in HER2-driven breast cancer.PMID 26276735Read ↗

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.Semantic proximity Read ↗

Resistance to Anti-HER2 Therapies in Breast CancerSemantic proximity Read ↗

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerSemantic proximity Read ↗

Mechanisms of resistance to HER2 target therapy.Semantic proximity Read ↗

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.Semantic proximity Read ↗

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.Semantic proximity Read ↗

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family BromodomainsSemantic proximity Read ↗

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.Semantic proximity Read ↗

Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancerSemantic proximity Read ↗

Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.Semantic proximity Read ↗

Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancerSemantic proximity Read ↗

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.